



Adaptive Blinded Sample Size Adjustment for Comparing Two Normal Means – A Mostly-Bayesian Approach

Andrew Hartley, PhD Associate Statistical Science Director

Summary

- The need for sample size adjustment (SSA)
- Review of standard approaches
- Intuition & logic underlying proposed approach
- Effects of blinded data on beliefs about mean treatment difference
- Comparing new approach vs. standard ones
 - Mean-Mean Absolute Deviation
 - Risk-adjusted Net Present Value (rNPV)
- Effects on estimation & power
- Sensitivity to Normal assumption
- Discussion Q&A, comments

Context

- Clinical trial Randomized, Blinded
- Comparing 2 normal means
- Sample size usually chosen to provide targeted level of statistical power
 - Power too high? ⇒ Waste of resources, unethical to expose too many patients
 - Power too low? ⇒ Might get equivocal results
- Power, for any given sample size, depends on
 - Δ = population mean treatment difference
 - Σ = population within-treatment variance (MSE)
- Problem: Usually,

Much uncertainty attends Δ and Σ

- ⇒ power cannot be determined precisely (!)
- ⇒ Hence, popularity of sample size adjustment

Standard Sample Size Adjustment Approaches

Common Steps

- At protocol planning stage, set provisional sample size target
- Collect some on-trial data
- Re-estimate Δ and/or Σ
- Re-estimate sample size requirement

Standard Sample Size Adjustment Approaches

Unblinded and blinded approaches exist

- Standard **Unblinded** approaches
 - Require
 - Data Monitoring Committee (DMC)
 - Adjusted test statistics (Cui-Hung-Wang 1999, Chen-DeMets-Lan 2004, etc.)—often are inefficient
 - Procedures for protecting blind
 - Complicate reporting / interpretation
 - Support re-estimating both Δ and Σ
- Standard Blinded approaches
 - Usually, based on S_b^2 = blinded (overall) sample variance
 - Approximately, $E(S_b^2) \Delta_0^2/4 = \Sigma$
 - So, Σ estimated as $S_b^2 \Delta_0^2/4$
 - Obviate DMC, adjusted statistics
 - Support re-estimating Σ only
 - Advisable only when Δ estimated with high precision (this severely curtails usefulness)

Proposed Blinded Sample Size Adjustment Method

- We have some prior ideas of plausible values of Δ and Σ; if we didn't, would we be running the clinical trial?
- Often, we can summarize these beliefs well using

$$\Delta \sim N(\theta, \tau^2)$$
 $\perp \perp \qquad \Sigma \sim Gamma(\alpha, \beta)$

Proposed Blinded Sample Size Adjustment Method (con't)


Recall

$$E(S_b^2 \mid \Sigma, \Delta) = \Sigma + k\Delta^2$$

where $k \rightarrow \frac{1}{4}$.


- Observing S_b^2 refines the prior beliefs concerning both Δ and Σ (not just concerning Σ)
 - If $Var(\Delta) < Var(\Sigma)$, then S_b^2 mainly shifts PDF of Σ
 - If $Var(\Sigma) < Var(\Delta)$, then S_b^2 mainly shifts PDF of Δ
- Example in which $Var(\Sigma)=Var(\Delta)...$

Effects of Blinded Data on Beliefs about Δ (1)




1.1. Expected and Observed Blinded Variance=(6.2931,5.03448).

Effects of Blinded Data on Beliefs about Δ (2)



1.2. Expected and Observed Blinded Variance=(6.2931,6.2931).

Effects of Blinded Data on Beliefs about Δ (3)



1.3. Expected and Observed Blinded Variance=(6.2931,7.55172).

Proposed Blinded SSA Procedure – How to Perform

 For each candidate N per treatment group, calculate "Predictive Power:"

$$\int_{0}^{\infty} \int_{\Theta} \left[\begin{array}{c} Conditional Power(\delta, \Sigma, N) \times \\ \pi_{\Delta} \left(\delta \mid \sigma^{2}, s_{b}^{2} \right) \partial \delta \pi_{\Sigma} \left(\sigma^{2} \mid s_{b}^{2} \right) \partial \Sigma \end{array} \right]$$

Integration subject to

$$\Sigma + k\Delta^2 = E[\Sigma + k\Delta^2 \mid S_b^2]$$

(Predictive Power = probability of statistical significance at the end of the trial, accounting for the uncertainties with respect to Δ and Σ)

 Choose N such that Predictive Power = target desired

Calculating $E[\Sigma + k\Delta^2 / S_b^2]$

- $E(S_b^2 \mid \Sigma, \Delta) = \Sigma + k\Delta^2$ where $k \cong \frac{1}{4}$.
- So, we could simply estimate $\Sigma + k\Delta^2$ as S_b^2
- However, bayesianly using prior information enhances estimation

General bayesian inferential result is that, if

$$\theta \sim N(\mu, \tau^2)$$
 & $X|\theta \sim N(\theta, \sigma^2)$

then

$$\theta \mid x \sim N(\mu(x), v^2)$$

where

$$\mu(x) = \frac{\sigma^2 \mu + \tau^2 x}{\sigma^2 + \tau^2}, \ v^2 = \frac{\sigma^2 \tau^2}{\sigma^2 + \tau^2}.$$

 \Rightarrow Improved estimate of θ is a weighted average between the *prior* expectation & the empirical estimate.

Calculating $E[\Sigma + k\Delta^2 / S_b^2]$ (con't)

$$\Delta \sim N(\theta, \tau^2)$$
 $\perp \perp \qquad \Sigma \sim Gamma(\alpha, \beta)$

$$\Rightarrow E(\Sigma + k\Delta^2) = \alpha\beta + k(\theta^2 + \tau^2)$$

 \Rightarrow Improved estimate of $\Sigma + k\Delta^2$ is

$$E[+ k\Delta^{2} | S_{b}^{2}] = \frac{a[\alpha\beta + k(\theta^{2} + \tau^{2})] + bS_{b}^{2}}{a + b}$$

for some a & b, as weights of $E(\Sigma + k\Delta^2)$ & S_b^2 .

a & b are the <u>sampling</u> variance & the <u>prior</u> variance.

New SSA Method - Summary of Steps

Identify

- a) Desired power
- Priors for Δ , Σ (indexed by θ , τ , α , β), using elicitation and/or historical data

2. Calculate

- a) S_b^2 (blinded sample variance)
- b) $E(\Sigma + k \Delta^2 | S_b^2)$ (if time allows)
- 3. For each candidate n (end-of-study sample size per group), calculate PredictivePower(n), integrating ConditionalPower(n, Δ , Σ) over parameter space subject to $\Sigma + k \Delta^2 = E(\Sigma + k \Delta^2 | S_b^2)$ or $\Sigma + k \Delta^2 = S_b^2$
- 4. Select *n* that achieves the predictive power closest to that desired.

Generalization: Comparing ≥3 Treatments

- Standard 1-way ANOVA
- Model: $y_{ij} = \mu + \alpha_i + \varepsilon_{ij}$
 - $\varepsilon_{ij} \sim N(0, \Sigma)$ (same Σ for all i)
 - -r treatment groups, indexed by i
 - -n independent measurements per group at End of Study, indexed by j
- $\alpha_1 + \alpha_2 + ... + \alpha_r = 0$ (to guarantee unique solution to normal equations)
- H_0 : $\alpha_i = 0 \forall i$
- Standard frequentist test statistic is

$$F = \frac{MSTr}{MSE}$$

• $F \sim F_{df(Tr),df(Error),\lambda}$ where

$$\lambda = \text{noncentrality} = \frac{n}{\sum} \sum_{i=1}^{r} \alpha_i^2$$

- Standard test of H_0 requires comparing F to upper quantile of $c = F_{df(Tr), df(Error), 0}$

Generalization: Comparing ≥3 Treatments (con't)

So, at the interim analysis, if $\theta = [\Sigma, \sum_{i=1}^{r} \alpha_i^2]$ were known, power conditional on θ could be given as

$$Pr(F \ge c / Data, \theta)$$

More realistically (unconditionally), predictive power is

 $\Pr(F \ge c|Data) = \int [ConditionalPower(\theta|Data)]\pi(\theta|Data)\partial\theta = \int [Condition$

$$\int \Pr(F \geq c \mid \Sigma, \sum_{i=1}^{r} \alpha_i^2) \times \left(\sum_{i=1}^{r} \alpha_i^2 \mid Data\right) \partial(\Sigma, \sum_{i=1}^{r} \alpha_i^2)$$

⇒ We want to find joint posterior PDF of

$$[\Sigma, \sum_{i=1}^{r} \alpha_i^2 | Data]$$

Generalization: Comparing ≥3 Treatments (con't)

• At interim, with *m* observations per group, (Blinded) total mean sum of squares is

$$MSTo = \frac{\sum_{ij} (y_{ij} - \bar{y})^2}{rm - 1}.$$

MSTo has conditional expectation

E(MSTo |
$$\Sigma$$
, $\sum_{i=1}^{r} \alpha_i^2$) = $\Sigma + \frac{m \sum_{i=1}^{r} \alpha_i^2}{rm-1}$

⇒Use MSTo

- 1. along with $E(\Sigma + \frac{m\sum_{i=1}^{r} \alpha_i^2}{rm-1})$ to estimate $\Sigma + \frac{m\sum_{i=1}^{r} \alpha_i^2}{rm-1}$ (as a weighted average)
- 2. to update joint prior PDF of $[\Sigma, \sum_{i=1}^{r} \alpha_i^2]$

Then, for each candidate n, integrate $Pr(F \ge c | \Sigma, \sum_{i=1}^{r} \alpha_i^2)$ over joint PDF of $[\Sigma, \sum_{i=1}^{r} \alpha_i^2 | MSTo]$, finding n that provides desired predictive power

Comparing Blinded Sample Size Adjustment Methods

- Alice came to a fork in the road. "Which road do I take?" she asked.
- "Where do you want to go?" responded the Cheshire Cat.
- "I don't know," Alice answered.
- "Then," said the cat, "it doesn't matter."
 - Lewis Carroll, Alice in Wonderland

⇒ Choices between methods are arbitrary, without a **loss function**



Comparing Blinded SSA Methods

- Objective: Minimize expected loss ("risk"), taking expectations over parameters (Δ, Σ) & data (S_b^2)
- One measure of risk:

$$MMAD =$$

 $Mean_{Data}[Mean_{\theta}(Absolute\ Deviation\ from\ Targeted\ Power|Data)]$

$$= \int_{0}^{\infty} \int_{\Theta} |Power(\delta, s_{b}^{2}, N) - 0.9| \pi_{\Delta} (\delta |s_{b}^{2}) \partial \delta f_{s_{b}^{2}} (s_{b}^{2}) \partial s_{b}^{2}$$

for N= sample size per treatment group

Most **established blinded** methods lead to similar sample size adjustments & (hence) similar MMADs, so method of Gould-Shih (StatMed, 1998) used as representing those.

Over a range of situations, the proposed method reduces MMAD 15% to 27% compared to those established methods...

Comparing G&S Procedure (N') vs. Proposed Procedure (N") - MMAD

- 10,000 simulations for each combination of
 - ✓ E(Δ)
 - $\checkmark Var(\Delta)$
 - $\checkmark E(\Sigma)$
 - $\checkmark Var(\Sigma)$
- MMAD(N")/MMAD(N')
 - ➤ Small Ratio ⇒ N" provides an advantage
 - > Found to lie between 0.73 & 0.85 for all combinations studied*
 - Smallest when Var(Σ)/Var(Δ) small
- Evidence of small
 - α inflation
 - bias of sample mean treatment difference
- *N" does <u>much</u> better than N' in minimizing mean-mean <u>squared</u> deviation (MMAD=Mean-mean absolute deviation from 90% Conditional Power)

Comparing G&S Procedure (N') vs. Proposed Procedure (N") - rNPV

- Objectives of pharmaceutical industry
 - Provide medicines that allow patients to
 - Live longer
 - Function more fully
 - Feel better (Medical Care)
 - Advance knowledge of human body (Science)
 - Reward researchers & investors (\$ Profit)
- A simple measure of expected <u>profit</u> for a clinical trial is

"risk-adjusted Net Present Value" (rNPV) =
[Payoff upon Trial Success][Probability of Success]
- Sampling Cost

where, in simple situations, [Probability of Success] can be approximated by predictive power,

 $\int [ConditionalPower(\theta)]\pi(\theta|Data)\partial\theta$


Comparing G&S Procedure (N') vs. Proposed Procedure (N") – rNPV (con't)

- That simple measure, rNPV, can be adapted to more complex situations by incorporating
 - Impacts of estimated treatment effect (mean treatment difference, hazard ratio, etc.) on sales forecast
 - Influences of additional trials on marketing approval
 - Delays in marketing approval due to larger sample sizes
 - Discounting cash flow (\$1 spent now is worth more than \$1 earned later)
 - Real Options...
- So, rNPV may be a satisfactory metric for comparing SSA procedures

Comparing G&S Procedure (N') vs. Proposed Procedure (N") – rNPV (con't)

rNPV for each method (N" & N'): For each candidate n, calculate

- <u>Unblinded</u> probability of success (predictive power)
- <u>Estimated</u> predictive power (varies between blinded methods)
- Payoff given trial success
 - In simplest situation, constant WRT n
 - However, may decrease due to erosion of patent life & discounting
- Sampling cost Increases linearly with n
- n maximizing rNPV




Comparing G&S Procedure (N') vs. Proposed Procedure (N") – rNPV (con't)

- N'' increases rNPV for almost all combinations $(\alpha,\beta,\theta,\tau)$
- Further investigation needed to ascertain conditions under which each is superior
- On following slide
 - Graph of

$$\frac{[rNPV(N'')-rNPV(N')]}{abs(rNPV(N'))}$$

– For 125 combinations of hyperparameters $(\alpha,\beta,\theta,\tau)$

Gain over GS2 Method, on $LN[Var(\Delta)/Var(\Sigma)]$ and $CV(\Delta)$




Sensitivity Analysis: t-distribution of Data

- Q: Does proposed PP method improve rNPV visà-vis GS method, if data are T₃ (i.e., 3 dof)?
 - Note if dof=1 or 2 then variance not well-defined
 - rNPV simulations of previous slides repeated
 - Extreme outliers occurred in raw data, causing computation problems for both GS & new SSA methods. Therefore, S_b^2 limited to 10 times its approx. expectation:


$$S_b^2 \le 10E(\Sigma + k\Delta^2) = 10[\alpha\beta + k(\theta^2 + \tau^2)]$$

Next: Comparison of gains over GS method, for Normal data vs. T_3 data.

Gain over GS2 Method, on LN[$Var(\Delta)/Var(\Sigma)$] and $CV(\Delta)$



Gain over GS2 Method, on LN[$Var(\Delta)/Var(\Sigma)$] and $CV(\Delta)$



Summary

- Unblinded SSA methods logistically challenging, requires statistical adjustments
- Established blinded SSA methods Useful only when Δ already estimated precisely
- Proposed blinded SSA method
 - Useful when both Δ and Σ are highly uncertain
 - Formally incorporates prior information
 - Appropriately adjusts PDFs of Δ and Σ
 - Generalizable to comparisons of ≥3 treatments
 - Compared to established blinded methods
 - Reduces mean-mean-absolute-deviation from targeted power
 - Almost always increases rNPV, for normal & t-distributed data
- For further information:
 - Andrew.Hartley@PPDI.com, 910-558-7147